Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Albumin in Decompensated Cirrhosis Guided by MICROB-PREDICT
NCT05056220Phase 3Recruiting
- Start
- Feb 2024
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of albumin (human) in decompensated cirrhosis and ascites (4 arms). Primary endpoint: Cumulative number of liver-related clinical outcomes at 6 months. Started Feb 2024; status: recruiting.
02
Drugs
albumin (human)
03
Conditions
decompensated cirrhosisascites
Beyond the preview
Go deeper on NCT05056220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056220.